Advaxis, Inc. (ADXS)

Teaching the Immune System to Fight Cancer™

The Advaxis Lm TechnologyTM, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.

Clinical Pipeline

Clinical Pipeline

Visit Advaxis Clinical Pipeline for more information on axalimogene filolisbac (ADXS-HPV) Clinical Program for HPV-associated cancers, which is currently placed on clinical hold.

View Clinical Pipeline

Industry Recognition

2015 EOY Regional Award Winner

Advaxis’s President and CEO was selected as a winner in the 2015 Ernst & Young (EY) Entrepreneur Of The Year® in New Jersey at a special event on June 25 at the Hyatt Regency in New Brunswick, N.J.

Learn More

2015 CFO of the Year Finalist

Advaxis' CFO Sara Bonstein was recognized as a finalist for NJBiz 2015 CFO of the Year at an awards ceremony on October 9 at the Palace at Somerset Park in Somerset, NJ.

Learn More


More Information

Recent Event

Jefferies Autumn 2015 Global Healthcare Conference

The May Fair Hotel, London